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SUCCESSFUL  TREATMENT OF AUTOIMMUNITY  IN NZB/NZW 
F1 MICE WITH MONOCLONAL ANT IBODY TO L3T4 
BY DAVID WOFSY AND WILLIAM E. SEAMAN 
From the Immunology/Arthritis Section, Veterans Administration Medical Center, and the 
Department ofMedicine, University of California, San Francisco, California 94121 
The advent of hybridoma technology has rekindled hopes of using antibodies 
as specific therapeutic agents (1-4). Several reports have focused attention on 
the potential use of monoclonal antibodies (mAb) 1 either as antitumor agents 
(4-15) or as immunosuppressive agents designed to facilitate organ transplanta- 
tion (16-21). Early therapeutic trials in humans have demonstrated that certain 
mAb can be used to retard the progression of lymphoid malignancy (10, 1 1) or 
to reverse renal allograft rejection (17, 18). However, in most cases, the beneficial 
effects of treatment have been transient (4, 12-17) due in part to the develop- 
ment of host immunity to the administered mAb (4, 9, 16, 17). 
Recently, (22) we treated three murine models for systemic lupus erythema- 
tosus (SLE) with biweekly injections of rat anti-T cell (anti-Thy-l.2) mAb in 
order to examine the role of T cells in the pathogenesis of murine lupus and to 
explore the possibility of using antilymphocyte mAb to treat autoimmunity. 
Treatment with anti-Thy-1.2 substantially reduced circulating T cells in all three 
strains (MRL/lpr, NZB/NZW FI, BXSB), despite development of antibodies to 
rat Ig. Therapy was beneficial in MRL/ lpr  mice. It reduced autoantibody 
production, retarded renal disease, and markedly prolonged life. In contrast, 
treatment did not reduce autoimmunity in NZB/NZW Fl (B/W) mice, and it 
caused fatal anaphylaxis n BXSB mice. These findings demonstrate hat antilym- 
phocyte mAb can serve as specific probes to examine the cells that contribute to 
autoimmunity. The results in MRL/ lpr  mice illustrate the potential therapeutic 
value of antilymphocyte mAb when a pathogenic ell subset can be identified. 
However, the results in BXSB mice emphasize qually the potential hazards of 
the host immune response to treatment with mAb. 
The development of a new rat mAb (GK1.5) reactive with mouse helper T 
cells provides an opportunity for a more selective approach to the study of T cell 
regulation of autoimmunity in murine lupus. This antibody recognizes a glyco- 
protein antigen, designated L3T4, that is the mouse homologue for the human 
T cell antigen termed Leu-3 or T4 (23). Like Leu-3/T4 in humans, L3T4 
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participates in the T cell response to class II major histocompatibility antigens 
(MHA II) on antigen-presenting cells (24-28). Antibody to L3T4 inhibits most 
MHA II-dependent T cell responses in vitro (25-27). Therefore, administration 
of mAb against L3T4 might alter immune responses in vivo and thereby 
influence the course of autoimmune disease. To test this hypothesis, we treated 
B/W female mice with weekly injections of GK1.5 (anti-L3T4) beginning at age 
4 mo. Treatment produced asustained reduction in circulating T cells expressing 
L3T4. It also dramatically reduced autoantibody concentrations, retarded renal 
disease, and prolonged life. Mice treated with rat anti-L3T4 mAb developed 
little or no antibody to the administered rat Ig. In contrast, control mice treated 
with purified nonimmune rat IgG developed high titers of antibody to rat Ig. 
These findings establish that autoimmune disease in B/W mice is T cell- 
dependent. They further demonstrate that: (a) mAb directed against helper T 
cells can significantly improve autoimmune disease in B/W mice; and (b) the 
beneficial effects of treatment with anti-L3T4 may not be complicated by the 
development of a host immune response to therapy. 
Materials and Methods 
Mice. B/W mice were bred in our colony at the San Francisco Veterans Administration 
Medical Center from NZB females, purchased from The Jackson Laboratory, Bar Harbor, 
ME, and NZW males purchased from Simonsen Laboratory, Gilroy, CA 
Treatment Regimen. 10 mice were treated with a rat IgG2b mAb against L3T4, 
designated GK1.5 (23). The hybridoma used to produce GK1.5 was generously provided 
by Dr. Frank W. Fitch, University of Chicago. Antibody to L3T4 was harvested as ascites 
from sublethally irradiated BALB/c mice, partially purified by ammonium sulfate precip- 
itation, dialyzed against phosphate-buffered saline, and quantified by protein electropho- 
resis and measurement of optical density. Treatment consisted of an initial intravenous 
injection of 2 mg of anti-L3T4, followed by weekly intraperitoneal injections (2 mg per 
mouse). In preliminary studies, we determined that an intravenous injection of 2 mg of 
anti-L3T4 produces saturation binding of circulating and splenic target cells, and substan- 
tial, though incomplete, binding of L3T4 ÷ lymph node cells and thymocytes (unpublished 
data). Two control groups were also studied: one group (10 mice) received weekly 2-mg 
injections of chromatographically purified rat IgG (Cappel Laboratories, Cochranville, 
PA); the other group (11 mice) received saline. 
Fluorescence Analysis of Lymphocyte Subpopulations. Peripheral blood was obtained from 
individual mice by retroorbital bleeding into heparinized pipettes. Mononuclear cells were 
separated by centrifugation over Lympholyte-M (Cedarlane Laboratories, Ontario, Can- 
ada), and quantified using a Coulter ZBI cell counter (Coulter Electronics, Inc., Hialeah, 
FL). Mononuclear cell subsets were identified by staining with fluorescein-conjugated 
mAb, as described previously (29). The antibodies used for analysis included: anti-Thy- 
1.2 (30-H12) to identify all T cells, anti-L3T4 (GKI.5) and anti-Lyt-2 (53-6) to identify 
the major T cell subsets, and anti-ThB (53-9) to identify B cells. Fluorescein-conjugated 
mouse anti-rat kappa chain mAb (MAR 18.5; B-D FACS Systems, Sunnyvale, CA) was 
used to detect anti-L3T4 on target cell surfaces. Except as noted, fluorescence analysis 
was always performed immediately before treatment, i.e., 1 wk after the previous injection. 
Assessment of Renal Disease. Blood urea nitrogen (BUN) was determined on samples 
from individual mice using a CentrifiChem System 400 (Union Carbide, Danbury, CT). 
Proteinuria was measured colorimetrically by the use of Albustix (Miles Laboratories Inc., 
Elkhart, IN). This produces an approximation ofproteinuria s follows: trace, 10 mg]dl; 
1+, 30 mg/dl; 2+, 100 mg/dl; 3+, 300 mg/dl; 4+, 1,000 mg/dl. All measurements of 
proteinuria were performed by an observer who had no knowledge of the given treatment. 
Measurement of Serum Antibodies to Double-stranded DNA. Anti-DNA antibody concen- 
trations were assessed by a solid phase enzyme-linked immunosorbent assay (ELISA) 
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derived from the method of Fish and Ziff (30). Immulon II polyvinyl microtitration trays 
were coated sequentially with a 50 #g/ml solution of poly-L-iysine (Sigma Chemical Co., 
St. Louis, MO) in 0.1 M Tris-HC! buffer, pH 7.3 (75 #g/well), a 20 #g/ml solution of 
poly(dA-dT) (Sigma Chemical Co.) in Tris buffer (75 #l/well), and a 2% solution of bovine 
serum albumin (BSA) (Sigma Chemical Co.) in Tris buffer (250 #i/well). Serum samples 
that had been serially diluted in Tris buffer containing 1% BSA and 2% bovine gamma 
globulin (BGG) (Sigma Chemical Co.) were then incubated at 75 #l/well for 1.5 h at room 
temperature. The wells were then washed five times and incubated with peroxidase- 
conjugated goat anti-mouse Ig that had been extensively absorbed with rat Ig (0.3 #g/ 
well; Cappel Laboratories). After incubation at room temperature for 1 h, the wells were 
washed five times and treated in the dark for 10 min with 0-phenylenediamine (100 #1/ 
well). The enzymatic reaction was stopped with 2 N H~SO4 (200 #l/well), and absorbance 
was measured at 490 nm. Serum from adult MRL/lpr and C57BL/6 mice served as 
positive and negative controls, respectively. The specificity of the assay was demonstrated 
using wells that had not been coated with poly(dA-dT). 
Measurement of Serum Antibodies to Rat Ig. Antibodies to rat Ig were measured by an 
ELISA technique similar to the one described above. Briefly, Immulon II polyvinyl 
microtitration trays were coated with rat Ig mAb (0.5 #g 30-H12/well) followed by 2% 
BSA in 0.1 M Tris-HC1 buffer. Serum samples were serially diluted in Tris buffer 
containing 1% BSA and 2% BGG, then incubated at 75 #l/well for 1.5 h at room 
temperature. The wells were then washed, incubated with peroxidase-conjugated goat 
anti-mouse Ig that had been absorbed with rat Ig, washed again, and then treated in the 
dark with o-phenylenediamine exactly as described above. Mouse anti-rat kappa chain 
mAb (MAR 18.5) and normal mouse serum served as positive and negative controls, 
respectively. 
Measurement of Serum IgM and IgG Levels. Serum concentrations of mouse IgM and 
IgG were measured by ELISA. lmmulon II polyvinyl microtitration trays were coated 
with a 10 #g/ml solution of either goat anti-mouse IgG or goat anti-mouse IgM (both, 
Cappel Laboratories), followed by 2% BSA in 0.1 M Tris-HCI buffer. Serum samples 
were serially diluted in Tris buffer containing 1% BSA and 2% BGG, then incubated at 
75 #l/well for 1.5 h at room temperature. The wells were then washed, incubated with 
peroxidase-conjugated goat anti-mouse Ig that had been absorbed with rat Ig, washed 
again, and then treated in the dark with 0-phenylenediamine, as described above. Purified 
mouse IgM and IgG (Miles Laboratories) were used to generate standard curves and 
document the specificity of the assay. 
Results 
Effect of Age on Circulating Lymphocyte Subpopulations in Untreated B/W Mice. In 
control B/W mice treated with saline, there was a spontaneous age-dependent 
reduction in circulating T lymphocytes (Fig. 1, A and B). The  number of 
circulating B lymphocytes remained relatively constant (Fig. 1 C). Although T 
cell counts fell by ~50% between 4 and 8 mo of  age, L3T4  + cells and Lyt-2 ÷ 
cells were comparably affected and, therefore, the L3T4/Lyt -2  (helper/suppres- 
sor) ratio remained constant (Fig. 1 D). Treatment  with weekly injections of  
nonimmune rat IgG did not affect the spontaneous progressive changes in 
circulating lymphocyte subpopulations in B/W mice. 
Effect of Treatment With Anti-L3T4 mAb on Circulating Lymphocyte Subpopula- 
tions. Treatment  of  B/W mice with weekly injections of anti-L3T4 mAb pro- 
duced a dramatic and sustained reduction in circulating L3T4 + lymphocytes 
(Fig. 1A). Circulating L3T4 ÷ cells were reduced by 30% 24 h after the first 
injection, by 90% 1 wk later, and by 95% thereafter. Fluorescence analysis of  
circulating lymphocytes using mouse anti -rat kappa chain mAb demonstrated 
persistence of  administered antibody on the few remaining target cells 7 d after 
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FIGURE 1. Circulating lymphocyte subpopulations in B/W mice treated with weekly injec- 
tions of saline (O), nonimmune rat IgG (&), or anti-L3T4 mAb (I) beginning at age 4 mo. 
Helper T cells, suppressor/cytotoxic T cells, and B cells were identified using fluorescein- 
conjugated anti-L3T4 mAb (A), anti-Lyt-2 (B), and anti-Thy B (C), respectively. The relative 
proportion of L3T4 + and Lyt-2 ÷ T cells is shown in D. 
injection. Staining with fluorescein-conjugated anti-Thy-1.2 mAb and anti-Lyt-2 
established that, after 1 wk of therapy, >90% of circulating T cells in treated 
mice expressed Lyt-2, indicating that the reduction in L3T4 + T cells reflected 
target cell depletion rather than antigen modulation. The effect of treatment 
with anti-L3T4 was specific. The number of circulating B cells and Lyt-2 + T 
cells remained stable in treated mice (Fig. 1, B and C). The mean L3T4/Lyt-2 
ratio in treated mice was 0.1:1, compared with 2.6:1", in untreated mice. 
Host Immune Response to Treatment. Control mice treated with nonimmune 
rat IgG all developed high titers of antibody to rat Ig (Fig. 2). Host antibodies 
were detectable 7 d after the first injection of rat IgG arm rapidly rose to a peak 
mean titer of 1:4,500. In contrast, only 3 of 10 mice treated with rat anti-L3T4 
mAb developed antibodies to rat Ig. In these mice, antibodies to rat Ig first 
appeared after 2-3 mo of therapy and were present only in relatively low titer 
(<1:400). 7 of the 10 treated mice never developed etectable antibody to rat 
Ig. This is in striking contrast to our previous observation that B/W mice treated 
with rat anti-Thy-l.2 mAb of the same isotype as anti-L3T4 all develop high 
titers of anti-rat Ig (22). 
Anti-L3T4 Reduces Autoimmunity. Treatment of B/W mice with anti-L3T4 
mAb prevented evelopment of high titers of antibody to double-stranded DNA 
(Fig. 3). Although small amounts ofanti-DNA antibody appeared within the first 
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FIGURE 2. Geometric mean titer (-~- SEM)of antibodies to rat Ig in B/W mice treated with 
saline (O), nonimmune rat IgG (A), or anti-L3T4 mAb (E). The shaded area indicates assay 
results using normal mouse sera as negative controls. 
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FIGURE 3. Geometric mean titer (~ SEM) of antibody to double-stranded DNA in 
B/W mice treated with saline (O), nonimmune rat IgG (A), or anti-L3T4 mAb (1). The shaded 
area indicates the titer of anti-DNA antibody (<1:200) in normal (C57BL/6) mice. 
2 mo of  therapy with ant i -L3T4, the titers of  anti -DNA antibody were markedly 
lower in treated mice than in control mice, and the titers remained low through- 
out the duration of  therapy. At age 8 mo, the geometric mean titer of  anti -DNA 
antibody was 1:2,200 ~ 1.2 in mice treated with saline, 1:1,500 ~ 1.5 in mice 
treated with non immune rat Ig, and 1:270 ;$1.1 in mice treated with ant i -L3T4 
(P < 0.0005 compared with either control group; Student's t test). The  reduction 
in anti-DNA antibody did not reflect a generalized reduction in total Ig levels in 
treated mice (Table I). After 4 mo of  treatment,  there was a slight reduction in 
the mean IgG concentration i treated mice that was not statistically significant. 
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TABLE I 
Effect of Treatment on lg Concentration 
Treatment 
lgM* IgG* 
4-mo-old 8-mo-old 4-mo-old 8-mo-old 
Saline 9.5 3= 0.2 9.2 3= 0.2 15.5 3= 0.2 15.7 3= 0.2 
Rat IgG 9.6 3= 0.2 9.6 3= 0.2 15.7 3= 0.3 15.5 3= 0.6 
Anti-L3T4 9.6 3= 0.2 10.3 3= 0.2* 15.5 3= 0.3 15.2 3= 0.3 
* Log~ titer (~ 3= SEM) as measured by ELISA. 
* P < 0.05 compared to pretreatment IgM levels and to IgM levels in both control groups. 
60-  
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FIGUnE 4. Mean BUN in B/W mice treated with saline (O), nonimmune rat lgG (&) or anti- 
L3T4 mAb (I).  
However, there was a significant increase in the mean IgM concentration i  
treated mice compared with pretreatment levels, and with IgM levels in control 
mice. Increased plasma IgM has been reported previously (31) in association with 
successful treatment of  B/W mice. 
Anti-L3T4 Reduces Renal Disease. The reduction in anti-DNA antibody con- 
centration in mice treated with anti -L3T4 was associated with a significant 
reduction in renal disease. Renal function, as assessed by BUN, deteriorated 
steadily in both control groups, but was preserved in mice treated with anti- 
LST4  (Fig. 4). Renal insufficiency occurred earliest in mice treated with non- 
immune rat IgG, perhaps as a consequence of  the host immune response to rat 
Ig. At age 7 mo, the mean BUN in mice treated with rat IgG was 34.2 _+ 12.1 
mg/dl, compared to 18.5 _+ 2.7 mg/dl in mice treated with saline (P < 0.05; 
Mann-Whitney U test) and 13.1 _+ 0.8 mg/dl in mice treated with anti-L3T4 
(P < 0.01 compared with rat IgG treatment; P < 0.05 compared with saline 
treatment). By 9 mo, the mean BUN in mice treated with saline rose to 38.0 + 
11.6 mg/dl, compared with 14.3 _+ 0.9 mg/dl in mice treated with anti-L3T4 (P 
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< 0.01). Severe proteinuria (--_3+) developed in 50-60% of  mice in each control 
group, but in none of  the mice treated with ant i -L3T4 (P < 0.05; chi-square 
analysis) (Fig. 5). Moderate proteinuria (2+) developed in 16 of  21 control mice 
but in only 2 of  10 treated mice (P < 0.05). These two mice were among the 
three treated mice that developed low titers of  antibody to rat Ig, suggesting 
that the immune response to rat Ig may have contr ibuted to the development of  
proteinuria. 
Anti-L3T4 Prolongs Survival. Treatment  with ant i -L3T4 mAb dramatically 
prolonged life (Fig. 6). Median survival was 9.3 mo in mice treated with saline 
and 7.6 mo in mice treated with rat IgG. In contrast, all of  the mice treated with 
ant i -L3T4 are still alive at 10 mo. The  difference in 10-mo survival between 
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FIGURE 5. Frequency of significant proteinuria in B/W mice treated with saline (O), nonim- 
mune rat IgG (&), or anti-L3T4 mAb (11). (.4) Percent of mice with proteinuria >2+ (100 
mg/dl). (B) Percent of mice with proteinuria >3+ (300 mg/dl). To reflect accurately the 
development ofrenal disease in all mice, each point reflects the current level of proteinuria in 
surviving mice, as well as the last measurement of proteinuria in deceased mice. 
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FIGURE 6. Survival in B/W mice treated with saline (O), nonimmune rat IgG (l), or anti- 
L3T4 mAb (11). 
WOFSY AND SEAMAN 385 
mice treated with anti-L3T4 and control mice is strongly significant (P < 0.001 
compared with the saline control group; P < 0.00001 compared with the rat IgG 
control group; chi-square analysis). The difference in mean survival between the 
two control groups is also statistically significant (P < 0.05; t test), i.e., treatment 
with nonimmune rat Ig accelerated mortality. 
Discussion 
To clarify the role of helper T cells in the pathogenesis of autoimmune disease 
in the B/W model for SLE, we treated female B/W mice with repeated injections 
of a rat mAb directed against he mouse helper T cell antigen, L3T4. Treatment 
depleted circulating target cells, reduced autoantibody production, retarded 
renal disease, and prolonged life. Moreover, treated mice produced little or no 
host antibodies to the administered rat mAb. These findings provide the first 
clear demonstration that autoimmune disease in B/W mice is T cell dependent. 
They further suggest hat mAb directed against specific helper T cell antigens 
may be effective in the treatment of certain autoimmune diseases, and that the 
therapeutic benefit may be achieved without provoking an undesirable, and 
potentially hazardous, immune response to the mAb. 
For two decades, the B/W strain has been studied (32, 33) as a model for SLE 
in humans. Early studies (34-37) focused attention on T cell abnormalities in 
B/W mice, emphasizing defects in suppressor T cell number and function. Recent 
studies, however, have cast doubt on the significance of these T cell abnormalities. 
For example, neonatal thymectomy has little effect on the course of autoimmu- 
nity in B/W mice (38), but elimination of a specific subset of B cells prevents 
autoimmune disease (39). Other studies, demonstrating B cell abnormalities, and 
indicating that 13 cell abnormalities may precede demonstrable T cell abnormal- 
ities in B/W mice, have suggested that autoimmunity in these mice may reflect a 
primary B cell defect, and that T cell defects may be secondary phenomena (40- 
43). Our results demonstrate conclusively that T cells, specifically helper T cells, 
play an important role in the pathogenesis of autoimmune disease in B/W mice. 
If primary defects occur in other cell types, particularly B lymphocytes, these 
cells nonetheless require helper T cells for the expression of disease. 
It has been postulated that autoimmunity in B/W mice might reflect selective 
loss of suppressor T cells (36, 37), perhaps as a consequence of the action of 
natural thymocytotoxic antibodies (44, 45). Our findings in untreated B/W mice 
show that, although progressive T lymphocytopenia occurs, there is no selective 
effect on suppressor (Lyt-2 +) T cells. Rather, both major T cell subsets are 
comparably reduced, and the L3T4/Lyt-2 ratio is unchanged. There is, thus, no 
numerical imbalance between helper and suppressor/cytotoxic T ells, although 
functional differences cannot be excluded. 
The L3T4 molecule is expressed on a distinct subpopulation of T cells 
previously referred to descriptively as helper T cells. More precisely, L3T4 
identifies T cells that respond to MHA II on antigen-presenting cells (24-27). 
The functional importance of the L3T4 molecule is demonstrated by the obser- 
vation that mAb against L3T4 blocks in vitro T cell responses to MHA II (25- 
27). The beneficial effects ofanti-L3T4 in B/W mice may, therefore, be due not 
only to target cell depletion, but also to direct inhibition of T cell responses that 
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are dependent on the recognition of MHA II. The latter mechanism would imply 
that autoimmunity, like immunity to foreign antigens, requires a T cell response 
to MHA II. Our results are compatible with this possibility, but they do not 
prove it. We previously (22) treated B/W mice with mAb against Thy-l.2, an 
antigen expressed on all T cells. Although treatment reduced circulating L3T4 ÷ 
T cells by 75%, there was a comparable reduction in Lyt-2 + T cells, and no 
improvement in autoimmunity. The failure of anti-Thy-1.2 to improve autoim- 
munity despite depletion of L3T4 + cells suggests either that: (a) regulation of 
autoimmunity in B/W mice involves a balance between L3T4 ÷ cells and Lyt-2 ÷ 
cells that is not disturbed by treatment with anti-Thy-l.2; or (b) successful 
treatment with anti-L3T4 requires functional impairment of the L3T4 molecule. 
An important observation i  our present studies was the relative lack of host 
immunity to the anti-L3T4 antibody. Previous attempts to use mAb as therapeu- 
tic agents in humans and in mice have been complicated by the development of
a host immune response to the mAb (4, 9, 16, 17, 22). In B/W mice treated with 
rat anti-Thy-l.2 mAb (subclass IgG2b), the development of antibody to rat Ig 
was associated with accelerated mortality, even though autoimmunity was not 
affected (22). In autoimmune BXSB mice, treatment with anti-Thy-l.2 caused 
fatal anaphylaxis (22). The current study reemphasizes the potential hazards of 
treatment with foreign Ig, because administration of purified nonimmune rat 
IgG significantly reduced survival. In this context, the weak host immune 
response to rat anti-L3T4 mAb (subclass IgG2b) takes on added significance. 
The ability to administer anti-L3T4 without generating high titers of host 
antibody to rat Ig may not only maximize the therapeutic effect of anti-L3T4, it 
may also minimize the risks associated with the host immune response to foreign 
protein. 
The lack of host immunity to repeated injections of anti-L3T4 is the first 
demonstration that anti-L3T4 can interrupt he immune response in vivo. It 
remains to be determined if anti-L3T4 will block the in vivo response to foreign 
antigens other than itself, although it has been demonstrated (25) that anti-L3T4 
can block in vitro responses to foreign antigens that are presented in association 
with MHA II. Immune recognition of MHA II can also be blocked both in vitro 
and in vivo by mAb against MHA II (46-49). One group of researchers (50-52) 
have treated murine models for several autoimmune diseases with mAb against 
MHA II. This treatment was effective in experimental utoimmune encephalitis 
(50) and experimentally induced myasthenia gravis (51). It also increased survival 
in B/W mice, even though it did not reduce autoantibody production (52). In 
mice, MHA II are expressed on macrophages, B cells, and activated T cells (53), 
but it is not known whether successful treatment with mAb against MHA II is 
associated with depletion of these cell types. In humans, MHA II are expressed 
not only on certain lymphoid cells, but also on blood vessel endothelial cells (54). 
This may account for the severe toxicity of mAb against MHA II in monkeys 
(55), which may complicate the use of anti-MHA II in humans. Unlike MHA II, 
L3T4 appears to be restricted in its expression to a distinct subpopulation of T 
lymphocytes and T lymphocyte precursors (24). Therefore, anti-L3T4 mAb may 
provide an alternative to the use of anti-MHA II mAb that would be more 
selective in its effect on the immune system. The human homologue for the 
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L3T4 antigen has been identified (23), and mAb against this antigen have already 
been used to prolong renal allograft survival in nonhuman primates (19). 
Treatment of B/W mice with anti-L3T4 had profound effects on the immune 
system that raise questions about the immune competence of treated mice. The 
reduction in L3T4 ÷ T cells creates an imbalance between T cell subpopulations 
that resembles the distribution of T cell subsets in acquired immunodeficiency 
syndrome (AIDS) in people (56). The beneficial reduction in antibodies to 
double-stranded DNA and antibodies to rat Ig may reflect a more generalized 
impairment of humoral immunity. Our studies do not establish the significance 
of these alterations in cellular and humoral immunity, but they do provide some 
preliminary insight. Despite a 10-fold reduction in autoantibody concentration, 
treatment with anti-L3T4 did not significantly depress Ig levels. Moreover, 
treated mice did not develop infectious complications, even though they were 
housed without special precautions in our main animal colony. Studies are 
currently in progress in our laboratory to determine the precise effects of 
treatment with anti-L3T4 on immune competence in normal and autoimmune 
mice. 
The immunologic abnormalities in B/W mice closely parallel the immunologic 
abnormalities underlying SLE in humans. T lymphocytopenia, mpaired sup- 
pressor T cell function, reduced lymphokine production, and B cell hyperactivity 
all occur in humans with SLE as well as in B/W mice, but the significance of 
these abnormalities remains controversial (32, 57-60). There is no fixed abnor- 
mality in the relative proportion of circulating T cell subsets in either B/W mice 
or humans with SLE (61), but our results make it clear that this does not exclude 
the possibility that T cells regulate autoimmunity in SLE. The similarities 
between SLE in humans and SLE in B/W mice suggest hat they may share 
common pathogenetic mechanisms. Our findings in B/W mice therefore support 
the hypothesis that autoimmunity in people with SLE is regulated by T cells. 
This hypothesis i consistent with recent studies indicating that total lymphoid 
irradiation (TLI) improves lupus nephritis in humans (62-64). Although the 
effect of TLI on lymphocyte subsets in SLE has not yet been determined, TLI 
causes prolonged epletion and impaired function of Leu-3/T4 + cells in people 
with rheumatoid arthritis (65-67). These observations add weight to the possi- 
bility that treatment with mAb against Leu-3/T4 would favorably influence the 
course of autoimmune disease in people with SLE. However, we believe that 
such treatment would be premature until the effects of anti-L3T4 on normal 
immune function have been thoroughly investigated. 
Summary 
Autoimmune NZB/NZW mice were treated with weekly injections of mono- 
clonal antibody (mAb) to L3T4, an antigen expressed on a distinct subpopulation 
of T cells that respond to class II major histocompatibility antigens. Treatment 
with anti-L3T4 depleted circulating target cells, reduced autoantibody produc- 
tion, retarded renal disease, and prolonged life relative to control mice treated 
either with saline or with purified nonimmune rat IgG. These findings establish 
that autoimmune disease in NZB/NZW mice is regulated by T cells. In contrast 
to mice treated with nonimmune rat IgG, mice treated with rat anti-LST4 mAb 
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developed little or no antibody to rat Ig. Thus, the benefits of  treatment with 
ant i -L3T4 were achieved while minimizing the risks associated with a host 
immune response to therapy. This study raises the possibility that treatment with 
mAb against Leu-3/T4,  the human homologue for L3T4,  might be effective in 
the treatment of  certain autoimmune diseases in people. 
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assistance in preparation of the manuscript. 
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